Fierce Biotech

Nasdaq volatility delays IPO, Almirall pulls drug over price, Topotarget to merge as PDUFA nears

Welcome to this week's edition of our EuroBiotech Report, in which we have news of how the rise and fall of U.S. biotech and med tech stocks is shaping decisions in Europe.

Fri, 18 Apr 2014 06:00:00 +0000

Biotech VCs wager $1.1B in Q1, starting the year with a flurry of new deals

Venture investing in the biotech sector hit the $1.1 billion mark in the first quarter of the year--a surprisingly strong showing for what has generally been a quiet season in the U.S. industry.

Fri, 18 Apr 2014 02:10:48 +0000

Corey Goodman backs $20M A round for heart drug biotech

Corey Goodman, the managing partner at venBio, is joining a group of VCs backing Ireland's Heart Metabolics, which is positioning a Phase III-ready heart disease drug for the clinic.

Thu, 17 Apr 2014 14:45:27 +0000

Pfizer, AstraZeneca back a new strategy for cancer drug R&D

A pair of pharma giants have partnered with a prominent cancer research charity in the U.K. on an innovative new approach to testing targeted oncology therapies, building on the country's national program for tumor testing in a way that may help make it a global center of cancer R&D.

Thu, 17 Apr 2014 14:24:45 +0000

Vital Therapies banks $54M in a downsized IPO retry

After pulling the plug on an $86 million float in biotech's halcyon 2013, Vital Therapies has made its way to Wall Street with a scaled-down $54 million offering, cash it will use to advance its drug-device combo for liver failure.

Thu, 17 Apr 2014 14:11:20 +0000

GlaxoSmithKline and Galapagos succeed in psoriasis after two setbacks

Galapagos and partner GlaxoSmithKline say their anti-inflammation candidate hit its mark in a mid-stage trial on psoriasis, a stroke of good news for a drug beset by developmental slipups.

Thu, 17 Apr 2014 13:29:19 +0000

Biotech upstart grabs $18M to study a new drug to protect pregnancies

A biotech startup with roots in Palo Alto, CA has raised $18 million in venture cash to open up a second mid-stage study of its lead therapy, looking to shape a reputation for itself in the lightly populated R&D world of reproductive medicine.

Thu, 17 Apr 2014 13:16:22 +0000

Which therapies top Thomson Reuters' list of new drugs to watch this year?

The industry analysts at Thomson Reuters put their heads together to tap the biggest new blockbusters in the making this year and surprised no one by capping the list with Gilead's Sovaldi.

Thu, 17 Apr 2014 12:31:18 +0000

Baxter's latest bleeding drug hits the mark in PhIII

Baxter charted another late-stage success in its growing hemophilia franchise, posting positive top-line results for an orphan bleeding disorder treatment.

Wed, 16 Apr 2014 15:36:40 +0000

Have the biotech bears run out of steam?

The Nasdaq biotech index is down more than 20 percent since February, which has caused considerable anguish among the gamblers wooed into the high-risk field as stocks boomed last year. But some analysts are betting that the worst is over and that the correction has run its course.

Wed, 16 Apr 2014 15:29:20 +0000